QIAseq Pan-cancer Multimodal Panel

The only one-day, low-input sample to sequencing workflow for simultaneous and comprehensive genomic profiling of DNA variants, RNA fusions and assessing TMB/MSI in solid tumors and heme malignancies


  • Single primer extension (SPE)-based QIAseq Multimodal technology enabling uniform and complete coverage of targets, including complex genes like CEPBA, and confident detection of known and novel fusions
  • Pre-optimized protocol to go from total nucleic acid extraction to preparation of UMI-containing, unique dual-indexed, NGS-ready libraries using a single-day workflow to enhance sensitivity, improve error correction and reduce sample index hopping
  • Pre-configured automation-compatible workflow solution with secondary analysis and variant interpretation for rapid onboarding, faster turnaround times and improved scalability
QIAseq Multimodal HC Panel (12)

Cat. No. / ID: 333942

Kit containing ALL reagents (except indices) sufficient to process 12 samples for multimodal (DNA and RNA) sequencing; fixed high content (HC) panel for a total of 24 reactions
QIAseq Multimodal HC Panel (12)
QIAseq Multimodal HC Panel (96)
QIAseq Pan-cancer Multimodal Panel适用于分子生物学应用。该产品不适用于疾病的诊断、预防或治疗。

Product Details

Developed for consolidated DNA and RNA enrichment and integrated analysis, this solution has a lower sample input requirement that is ≥50% less than conventional approaches for increased compatibility with samples of limited availability. It also enables a lower overall sequencing requirement compared to separate DNA and RNA approaches, resulting in reduced per-sample costs. The QIAseq Pan-cancer Multimodal Panel provides a sample to sequencing workflow that is up to 2 days faster, with more than 50 fewer steps than similar protocols


Explore the available targets.


Recent advances in NGS chemistries, platforms and bioinformatics pipelines are enabling users to efficiently interrogate biological samples for changes in DNA and RNA. Current approaches, however, require the use of 2 separate workflows to prepare libraries from separate DNA and RNA isolates. Limitations of such approaches include:

  • Large amounts of sample material required for generating sufficient amounts of input DNA and RNA for multiple workflows
  • Added complexity of deriving integrated insights from results of different technical approaches, each with its own innate bias
  • Inefficient use of resources
  • Long turnaround times

To overcome the limitations associated with current approaches, the QIAseq Pan-cancer Multimodal Panel starts with total nucleic acids (or DNA and RNA) as input, and generates UDI-containing, Illumina-compatible targeted DNA and RNA libraries using a single-day, consolidated workflow. In addition, the QIAseq Pan-cancer Multimodal Panel has been designed for use with low-yield and poor-quality biological samples.


Workflow of the QIAseq Pan-cancer Multimodal Panel

The QIAseq Pan-cancer Multimodal Panel workflow can be used to prepare sequencing-ready libraries in a single day. The library insert size is approximately 150 bp, making the QIAseq Pan-cancer Multimodal Panel highly compatible with low-quality samples, such as FFPE samples.

 Learn more about the unique and innovative workflow of the QIAseq Pan-cancer Multimodal Panel.


Robust detection of DNA and RNA biomarkers

The QIAseq Pan-cancer Multimodal Panel can be used to reliably detect DNA and RNA biomarkers using a consolidated workflow from total nucleic acids. The ability of the QIAseq Pan-cancer Multimodal Panel to simultaneously detect DNA and RNA biomarkers has been benchmarked against two separate workflows (namely, QIAseq Targeted DNA and QIAseq Targeted RNAscan Panels). 


See figures


The QIAseq Pan-cancer Multimodal Panel can be used to interrogate different types of biomarkers using a consolidated workflow from total nucleic acids, which can be isolated using dedicated sample isolation protocols that have been developed specifically for the QIAseq Pan-cancer Multimodal Panel.

This innovative technology is well suited for addressing the challenges in comprehensive genomic profiling (CGP), where different types of biomarkers are assessed from a single sample. In addition, it is useful for biomarker discovery as multi-omic approaches and integrated analysis are key to providing deeper and more relevant insights.



Supporting data and figures


产品介绍与指南 (5)
State-of-the-art technologies to fast-track and streamline NGS workflows
QIAseq Multimodal Analytical Technology
QIAseq Multimodal: The power of one
Simultaneous DNA and RNA profiling from a single, low-input sample in a day
试剂盒操作手册 (1)
Supplementary Files (1)
List of gene targets for QIAseq Pan-cancer Multimodal Panel